59.62
+3.69%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Krebs Biochemicals and Industries
Its shares trade on NSE under the ticker KREBSBIO.NS. It has been listed since 2 March 1994. In the fiscal year to 31 March 2025, it reported revenue of ₹433.1m and a net loss of ₹269.4m. At that date it held total assets of ₹1.69bn and shareholders' equity of −₹1.46bn.
Krebs Biochemicals & Industries Ltd. engages in the manufacture and sale of pharmaceutical ingredients and intermediates. The company is headquartered in Hyderabad, Telangana. The firm develops commercially viable biotech processes for application in medicine, agriculture and industry. The company is also engaged in chemical synthesis, fermentation and enzymatic technologies. The company manufactures various products, such as Androstenedione for use as steroid intermediate, and Lovastatin and Simvastatin for anti-cholesterol. The company also undertakes contract manufacturing for pharmaceutical and multinational companies and developing products for sale in global markets. The company has also products in the pilot or research and development stages, which include Amlodipine, Cetirizine, Orlistat, Serratiopepetidase, Telmisartan and Phenylephrine. The company has two manufacturing facilities, one is located at Regadichelaka, Nellore District, and another one located at Kothapalli Village, Kasimkota Mandal, Visakhapatnam District, Andhra Pradesh, India.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 2 Mar 1994
- Employees
- 210
- Website
- krebsbiochem.com ↗
Leadership
Pay as last reported
- Dr. R. RaviNon-Executive Chairman of the Board, since 2015IDR 2.1m
- Mr. Ritesh JainChief Financial Officer
- Mr. Rakesh KalbateCompliance Officer, Company Secretary
- Mr. Pabitra BhattacharyaManaging Director, Additional Director, since 2021IDR 2.0m
- Mr. Avinash RaviNon-Executive DirectorIDR 5.0m
- Mr. Jitendra ShahNon-Executive Director
- Mr. Satya ChigurupatiAdditional Independent Director
- Mr. Sumanth KarlapudiAdditional Independent Director
- Mr. Popatlal KathariyaAdditional Independent Director
- Ms. Dipti ShahAdditional Independent Director
- Mr. Satish KhivsaraNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Krebs Biochemicals employs 210 full-time employees in Hyderabad, India.
- The company manufactures Androstenedione as a steroid intermediate for pharmaceutical use.
- Krebs Biochemicals develops biotech processes for medicine, agriculture, and industry applications.
Weaknesses
- Krebs Biochemicals has two manufacturing facilities in Andhra Pradesh, India.
- The company focuses on pharmaceutical ingredients and intermediates without diversification.
- Krebs Biochemicals has products in pilot or R&D stages like Amlodipine and Cetirizine.
Opportunities
- Krebs Biochemicals develops products for global markets including Lovastatin and Simvastatin.
- The company undertakes contract manufacturing for multinational pharmaceutical firms.
- Krebs Biochemicals has facilities in Nellore and Visakhapatnam for chemical synthesis and fermentation.
Threats
- Krebs Biochemicals faces competition from pharmaceutical companies in India.
- The company's reliance on R&D products like Orlistat and Serratiopeptidase may delay market entry.
- Krebs Biochemicals operates in the Health Care sector with high regulatory requirements.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.